Drug Profile
HIV vaccine - Abzyme Research
Alternative Names: Abzentek; E-VAC; Synthetic electrophilic vaccine - Abzyme ResearchLatest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator University of Texas Health Science Center at Houston
- Developer Abzyme Research Foundation; University of Texas Health Science Center at Houston
- Class Viral vaccines
- Mechanism of Action CD4 antigen inhibitors; HIV envelope protein gp120 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for preclinical development in HIV-infections in USA
- 28 Jan 2020 No recent reports of development identified for preclinical development in HIV-infections(Prevention) in USA
- 09 Dec 2015 Preclinical trials in HIV infections (Prevention) in USA (unspecified route)